Covalent guanosine mimetic inhibitors of G12C KRAS

Yuan Xiong, Jia Lu, John Hunter, Lianbo Li, David Scott, Hwan Geun Choi, Sang Min Lim, Anuj Manandhar, Sudershan Gondi, Taebo Sim, Kenneth D. Westover, Nathanael S. Gray

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Ras proteins are members of a large family of GTPase enzymes that are commonly mutated in cancer where they act as dominant oncogenes. We previously developed an irreversible guanosine-derived inhibitor, SML-8-73-1, of mutant G12C RAS that forms a covalent bond with cysteine 12. Here we report exploration of the structure−activity relationships (SAR) of hydrolytically stable analogues of SML-8-73-1 as covalent G12C KRAS inhibitors. We report the discovery of difluoromethylene bisphosphonate analogues such as compound 11, which, despite exhibiting reduced efficiency as covalent G12C KRAS inhibitors, remove the liability of the hydrolytic instability of the diphosphate moiety present in SML-8-73-1 and provide the foundation for development of prodrugs to facilitate cellular uptake. The SAR and crystallographic results reaffirm the exquisite molecular recognition that exists in the diphosphate region of RAS for guanosine nucleotides which must be considered in the design of nucleotide-competitive inhibitors.

Original languageEnglish (US)
Pages (from-to)61-66
Number of pages6
JournalACS Medicinal Chemistry Letters
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Guanosine
Diphosphates
Nucleotides
ras Proteins
Molecular recognition
Covalent bonds
GTP Phosphohydrolases
Prodrugs
Diphosphonates
Oncogenes
Cysteine
Enzymes
SML-8-73-1
Neoplasms

Keywords

  • ActivX
  • Bioisostere
  • Bisphosphonate
  • Covalent inhibitor
  • CPM
  • Drug design
  • GDP mimetic
  • KRAS G12C

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Organic Chemistry

Cite this

Xiong, Y., Lu, J., Hunter, J., Li, L., Scott, D., Choi, H. G., ... Gray, N. S. (2017). Covalent guanosine mimetic inhibitors of G12C KRAS. ACS Medicinal Chemistry Letters, 8(1), 61-66. https://doi.org/10.1021/acsmedchemlett.6b00373

Covalent guanosine mimetic inhibitors of G12C KRAS. / Xiong, Yuan; Lu, Jia; Hunter, John; Li, Lianbo; Scott, David; Choi, Hwan Geun; Lim, Sang Min; Manandhar, Anuj; Gondi, Sudershan; Sim, Taebo; Westover, Kenneth D.; Gray, Nathanael S.

In: ACS Medicinal Chemistry Letters, Vol. 8, No. 1, 01.01.2017, p. 61-66.

Research output: Contribution to journalArticle

Xiong, Y, Lu, J, Hunter, J, Li, L, Scott, D, Choi, HG, Lim, SM, Manandhar, A, Gondi, S, Sim, T, Westover, KD & Gray, NS 2017, 'Covalent guanosine mimetic inhibitors of G12C KRAS', ACS Medicinal Chemistry Letters, vol. 8, no. 1, pp. 61-66. https://doi.org/10.1021/acsmedchemlett.6b00373
Xiong, Yuan ; Lu, Jia ; Hunter, John ; Li, Lianbo ; Scott, David ; Choi, Hwan Geun ; Lim, Sang Min ; Manandhar, Anuj ; Gondi, Sudershan ; Sim, Taebo ; Westover, Kenneth D. ; Gray, Nathanael S. / Covalent guanosine mimetic inhibitors of G12C KRAS. In: ACS Medicinal Chemistry Letters. 2017 ; Vol. 8, No. 1. pp. 61-66.
@article{a087dd30416b4532bcb2e9aecd3dca00,
title = "Covalent guanosine mimetic inhibitors of G12C KRAS",
abstract = "Ras proteins are members of a large family of GTPase enzymes that are commonly mutated in cancer where they act as dominant oncogenes. We previously developed an irreversible guanosine-derived inhibitor, SML-8-73-1, of mutant G12C RAS that forms a covalent bond with cysteine 12. Here we report exploration of the structure−activity relationships (SAR) of hydrolytically stable analogues of SML-8-73-1 as covalent G12C KRAS inhibitors. We report the discovery of difluoromethylene bisphosphonate analogues such as compound 11, which, despite exhibiting reduced efficiency as covalent G12C KRAS inhibitors, remove the liability of the hydrolytic instability of the diphosphate moiety present in SML-8-73-1 and provide the foundation for development of prodrugs to facilitate cellular uptake. The SAR and crystallographic results reaffirm the exquisite molecular recognition that exists in the diphosphate region of RAS for guanosine nucleotides which must be considered in the design of nucleotide-competitive inhibitors.",
keywords = "ActivX, Bioisostere, Bisphosphonate, Covalent inhibitor, CPM, Drug design, GDP mimetic, KRAS G12C",
author = "Yuan Xiong and Jia Lu and John Hunter and Lianbo Li and David Scott and Choi, {Hwan Geun} and Lim, {Sang Min} and Anuj Manandhar and Sudershan Gondi and Taebo Sim and Westover, {Kenneth D.} and Gray, {Nathanael S.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1021/acsmedchemlett.6b00373",
language = "English (US)",
volume = "8",
pages = "61--66",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Covalent guanosine mimetic inhibitors of G12C KRAS

AU - Xiong, Yuan

AU - Lu, Jia

AU - Hunter, John

AU - Li, Lianbo

AU - Scott, David

AU - Choi, Hwan Geun

AU - Lim, Sang Min

AU - Manandhar, Anuj

AU - Gondi, Sudershan

AU - Sim, Taebo

AU - Westover, Kenneth D.

AU - Gray, Nathanael S.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Ras proteins are members of a large family of GTPase enzymes that are commonly mutated in cancer where they act as dominant oncogenes. We previously developed an irreversible guanosine-derived inhibitor, SML-8-73-1, of mutant G12C RAS that forms a covalent bond with cysteine 12. Here we report exploration of the structure−activity relationships (SAR) of hydrolytically stable analogues of SML-8-73-1 as covalent G12C KRAS inhibitors. We report the discovery of difluoromethylene bisphosphonate analogues such as compound 11, which, despite exhibiting reduced efficiency as covalent G12C KRAS inhibitors, remove the liability of the hydrolytic instability of the diphosphate moiety present in SML-8-73-1 and provide the foundation for development of prodrugs to facilitate cellular uptake. The SAR and crystallographic results reaffirm the exquisite molecular recognition that exists in the diphosphate region of RAS for guanosine nucleotides which must be considered in the design of nucleotide-competitive inhibitors.

AB - Ras proteins are members of a large family of GTPase enzymes that are commonly mutated in cancer where they act as dominant oncogenes. We previously developed an irreversible guanosine-derived inhibitor, SML-8-73-1, of mutant G12C RAS that forms a covalent bond with cysteine 12. Here we report exploration of the structure−activity relationships (SAR) of hydrolytically stable analogues of SML-8-73-1 as covalent G12C KRAS inhibitors. We report the discovery of difluoromethylene bisphosphonate analogues such as compound 11, which, despite exhibiting reduced efficiency as covalent G12C KRAS inhibitors, remove the liability of the hydrolytic instability of the diphosphate moiety present in SML-8-73-1 and provide the foundation for development of prodrugs to facilitate cellular uptake. The SAR and crystallographic results reaffirm the exquisite molecular recognition that exists in the diphosphate region of RAS for guanosine nucleotides which must be considered in the design of nucleotide-competitive inhibitors.

KW - ActivX

KW - Bioisostere

KW - Bisphosphonate

KW - Covalent inhibitor

KW - CPM

KW - Drug design

KW - GDP mimetic

KW - KRAS G12C

UR - http://www.scopus.com/inward/record.url?scp=85020907542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020907542&partnerID=8YFLogxK

U2 - 10.1021/acsmedchemlett.6b00373

DO - 10.1021/acsmedchemlett.6b00373

M3 - Article

C2 - 28105276

AN - SCOPUS:85020907542

VL - 8

SP - 61

EP - 66

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 1

ER -